We provide innovative therapeutic solutions that improve the quality of life for cancer patients, based on ANGel platform, which demonstrates excellent safety with high efficacy against cancer cells and low toxicity to normal cells.
To prepare for the patent expiration era of immuno-oncology drugs starting in 2025, we will transfer our platform technology to global pharmaceutical companies and grow into a leading player in the global market by securing indications for various cancer types.
By pioneering new areas of cancer treatment through collaboration with innovative technologies, in-house experts, and external partners, we aim to open a new era of overcoming diseases.
Our company will grow to become an organization that significantly increases the life expectancy of patients with innovative treatments for hard-to-treat cancers, while reducing the side effects that occur during the treatment process, allowing patients and their families to be free from suffering.
OncoLab is continuously hiring talented individuals in the field of biotechnology. Those interested in applying are encouraged to submit their documents via email.